Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension - Zineh, I; Beitelshees, AL; Gaedigk, A; Walker, JR; Pauly, DF; Eberst, K (Clin Pharmacol Ther., 2004)
et al.